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Abstract
Background Radiofrequency ablation (RFA) treatment outcomes vary for unknown reasons. One hypothesis is that variations 
in Barrett’s epithelial thickness (BET) are associated with reduced RFA efficacy for thicker BET and strictures for thinner 
BET. Volumetric laser endomicroscopy (VLE) is an imaging modality that acquires high-resolution, depth-resolved images 
of BE. However, the attenuation of light by tissue and the lack of layering in Barrett’s tissue challenge BET measurements 
and the study of relationships between thickness and RFA outcomes. We aimed to quantify BET and compared the reliability 
of standard and contrast-enhanced VLE images.
Methods Baseline VLE scans from BE patients without prior ablative therapy and a Prague (M) length of > 1 cm were 
obtained from the US VLE Registry. An algorithm was applied to the VLE images to flatten the mucosal surface and enhance 
the contrast of different esophageal wall layers. Subsequently, BET was measured by two independent VLE readers using 
both contrast- and non-contrast-enhanced datasets. In order to validate these adjusted images, intra- and interobserver agree-
ments were calculated.
Results VLE scans from fifty-seven patients were included in this study. BET was measured at eight equidistant locations on 
the selected cross-sectional images at 0.5 cm intervals from the GEJ to the proximal-most extent of BE. The intra-observer 
coefficients of the two readers for the contrast-enhanced images were 0.818 (95% CI 0.798–0.836) and 0.890 (95% CI 
0.878–0.900). The interobserver agreement for the contrast-enhanced images (0.880; 95% CI 0.867–0.891) was significantly 
better than for the original images (0.778; 95% CI 0.754–0.799).
Conclusion We developed an algorithm that improves VLE visualization of the mucosal layers of the esophageal wall and 
enables rapid and reliable measurement of BET. Interobserver variability measurements were significantly reduced when 
using contrast enhancement. Studies are underway to correlate BET with treatment response.
Keywords Barrett’s esophagus (BE) · Barrett’s esophageal thickness (BET) · Volumetric laser endomicroscopy (VLE) · 
Radiofrequency ablation (RFA)
Barrett’s Esophagus (BE) is a premalignant condition of the 
esophagus that results from chronic gastroesophageal reflux. 
BE has an annual risk of progression to adenocarcinoma 
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of up to 0.63% [1], and the survival of adenocarcinoma is 
low. Radiofrequency ablation (RFA) is used to eradicate 
flat BE tissue that has demonstrated transformation to early 
intra-epithelial neoplasia (i.e., low-grade or high-grade dys-
plasia) and uses high-frequency energy through an external 
electrode array on a circumferential (3-cm balloon) or focal 
delivery device, with a reproducible depth of ablation [2]. 
RFA results in complete response of intestinal metaplasia 
(CRIM) in 54.3–100% [3]. In addition to incomplete treat-
ment, approximately 7.7–11.6% of treated patients experi-
ence esophageal strictures [4, 5]. However, the reasons for 
these varying treatment outcomes are poorly understood. We 
hypothesize that variations in Barrett’s epithelial thickness 
(BET) are associated with reduced RFA efficacy for thicker 
BET and strictures for thinner BET.
The recent development of volumetric laser endomicros-
copy (VLE) allows high-resolution, detailed cross-sectional 
imaging of esophageal layers. VLE signal attenuation and 
the frequent lack of obvious layering in BE complicate the 
measurement of BET. In this study, we aimed to develop 
and validate a method to simplify BET measurements and 
improve measurement reliability. A simple and reproducible 
method to measure epithelial thickness is critical for study-
ing the relationship between BET and outcomes. Assuming 
a correlation, BET could be used for real-time determina-
tion of whether fixed-dose RFA is optimal, or deeper thera-
pies, such as cryoablation or endoscopic mucosal resection 
(EMR), should be employed.
Materials and Methods
Volumetric Laser Endomicroscopy
This second-generation VLE device uses a balloon-centered 
probe, with a balloon diameter of 14, 17, or 20 mm and a 
length of 6 cm. The balloon probe is passed through the 
working channel of the endoscope. When located in the dis-
tal esophagus, the balloon is inflated and the optics within 
the probe is helically scanned over the longitudinal extent 
of the balloon in 90  s, generating 1200 cross-sectional 
images of depth-resolved, backscattered infrared light. VLE 
images have an axial resolution of 7 µm, a lateral resolution 
of approximately 40 µm, and an imaging depth of approxi-
mately 3 mm [6]. These imaging characteristics potentially 
make VLE ideal for precise BET measurements.
Patient Selection
We performed a nested cohort study from the US VLE regis-
try (NCT02215291) containing scans of 1000 patients from 
eighteen sites. We included all patients with a baseline VLE 
scan, followed by RFA and at least a Barrett’s length (Prague 
M) of 1 cm. Patients with prior ablative therapy or patients 
without a follow-up examination were excluded. All scans 
were performed from May 2015 to October 2016 using sec-
ond-generation VLE probes. Informed consent was signed at 
the time of inclusion to the registry. The institutional reviews 
boards of all sites approved the registry study at its outset.
Selection of Measurement Locations
After determination of the GEJ, defined as the proximal end 
of both gastric folds and crypt architecture, a characteristic 
VLE finding is described by Gupta et al. [7]. Target VLE 
images were selected at 0.5 cm (100 cross sections) inter-
vals from the GEJ up to the proximal-most extent of the 
Barrett’s segment, as visible on the VLE scan. In shorter 
BE segments, the median tomogram image was chosen. In 
case of severe dilation (balloon–surface contact < 50%) or 
an extremely decentered probe, the closest image that met 
the criteria was selected.
Contrast Enhancement Algorithm
Identification of the epithelial boundary in VLE images can 
be challenging due to signal attenuation that occurs as a 
function of depth and the fact that the images are displayed 
in logarithmic scale. To address this problem, a contrast 
enhancement algorithm [8] was developed to compensate 
this signal attenuation and highlight the esophageal wall 
layers. The methodology also included a technique for flat-
tening the tissue surface [9]. Surface flattening expedites 
BET measurements by allowing the user to delineate a single 
point corresponding to the mucosa–submucosa boundary at 
each image’s circumferential measurement location.
Initially, the target tomogram image stacks were opened 
in (two-dimensional) polar coordinates (Fig. 1b). Then, a 
previously described algorithm by Ughi et al. (2016) [9] 
was used to locate the esophageal wall and flatten the tissue 
surface (Fig. 1c). Following surface flattening, OCT attenu-
ation compensation was applied using the method described 
in Teo et al. [8]. Attenuation-compensated frames were 
automatically contrast enhanced based on the histogram 
computed from a region of interest that spanned the entire 
image and was 400 pixels deep (Fig. 1d). After flattening, 
attenuation compensation, and contrast enhancement, eight 
equidistant lines (every 45°) were overlaid onto the images 
to denote the angular locations where BET measurement 
locations were to be made (Fig. 1e). All processing was per-
formed in ImageJ (imagej.nih.gov/ij/;1.51p) using custom 
macros and Java plugins.
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Measurements of Thickness
BET was defined as the distance between the balloon–epi-
thelium interface and the superficial edge of the deepest 
lamina propria. Since the surface was flattened, for each pre-
determined circumferential location (red lines in Fig. 1d), 
measuring BET simply amounted to clicking on the most 
superficial portion of the deepest lamina propria, on every 
overlaid line (Supplementary Figure), using ImageJ’s point 
selection tool with automatic measurements (“on”). In each 
cross section (both contrast-enhanced and non-contrast-
enhanced), the eight measurements were performed two 
times (“T1” and “T2”) with a 3–10 months’ interval by a 
research fellow (I.L.), trained on VLE image interpretation, 
and a VLE expert (G.T.).
Pixel distances were calibrated to physical distances (µm) 
by using the known pixel dimensions (5.85 µm/pixel) and 
an estimate of the tissue refractive index (n = 1.4). Lines 
that crossed regions of the image that did not contain BE or 
where the surface flattening algorithm failed were excluded 
from the analysis.
Statistical Analysis
SPSS 24 software for Windows (IBM Corp, Armonk, NY) 
was used to perform the statistical analysis and to produce 
the graphs. We used standard descriptive statistics to analyze 
the baseline patient characteristics. We assessed the relation 
between both individual thickness measurements and mean 
thickness per patient with age, BMI, Prague length, and his-
tology by calculating a Pearson’s, Spearman’s (in case of 
a non-normal distribution), or Kendall’s tau (in case of an 
ordinal variable) correlation coefficient.
We estimated the consistency between the research fel-
low and the VLE expert in the contrast-enhanced and the 
non-contrast-enhanced images, separately. Intra-observer 
agreements between the measurements made by the research 
fellow and VLE expert on both contrast-enhanced and non-
contrast-enhanced images were calculated. This resulted in 
four intra-class correlation coefficients (ICC; two-way mixed 
model), including 95% CIs. The Mann–Whitney U and Chi-
square test were used to compare means and percentages, 
respectively.
The standard deviation of the intra-observer difference of 
the ‘T1’ and ‘T2’ measurements in the contrast-enhanced 
images was used to estimate the range of difference that is 
acceptable for BET measurements.
Results
Patient Characteristics and Measurement Selection
Seventy-seven patients from the US VLE registry met the 
inclusion criteria. Twenty scans were subsequently excluded 
because of the absence of either visible BE or the quality of 
the scan did not allow BET measurement (Fig. 2a). Patients 
were predominantly male (75.4%) and had a mean age of 
63.4 (SD 10.8). The median Prague (C circumferential and 
M maximal extent) length at baseline procedure was C1M3. 
Of all patients, 10.5% had non-dysplastic BE, 8.8% were 
indefinite for dysplasia, 49.1% had LGD, 24.6% HGD and 
7% EAC (Table 1).
A total number of 321 cross sections were selected ran-
domly including 2568 measurement locations. After an ini-
tial screening of the measurement locations, 1068 locations 
Surface
Flattening
Scan 
Conversion
Standard VLE 
Image
(Cartesian  
Coordinates) Attenuation 
Compensation
& Contrast 
Enhancement
BET
Measurement 
Locations
A
B C D E
Fig. 1  Graphical overview of the contrast enhancement algorithm. (a) 
Standard VLE tomogram image, opened in Cartesian coordinates; (b) 
VLE tomogram image opened in polar coordinates; (c) VLE image 
after surface tissue flattening; (d) VLE image after OCT attenuation 
compensation and contrast enhancement; (e) VLE image after run-
ning the complete algorithm and placement of eight equidistant lines 
denoting the BET measurement locations
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were excluded due to non-BE tissue (36%) or failure of the 
surface finding (flattening) algorithm (6%) (Fig. 2b). The 
mean number of measurements per patient was 26 (95% CI 
21–31).
Thickness per Patient
The mean BETs measured from the attenuation-compen-
sated, contrast-enhanced images by VLE expert T1, VLE 
expert T2, research fellow T1, and research fellow T2 were 
436.2 µm (IQR 200.6), 448.6 µm (IQR 183.9), 395.6 µm 
(IQR 175.6), 398.5  µm (IQR 178.9), respectively. The 
mean BET per patient ranged from 223.63 µm–257.07 µm 
to 669.78 µm–705.41 µm (Fig. 3) for the contrast-enhanced 
measurements. Correlations were found between BET and 
BMI, Prague C, and histology (Table 2). Thickness did not 
depend on gender (male 407.1 µm vs. female 376.5 µm, 
P > 0.05), Prague (M) length, or age.
Intra‑observer Agreement
We compared the results of the measurements done by 
both the VLE expert and the research fellow. The consist-
ency of the measurements performed was “very good” with 
an intra-class coefficient of 0.818 (95% CI 0.798–0.839; 
Table 3, Fig. 4a) for the VLE expert and 0.890 (95% CI 
0.878–0900; Table 3, Fig. 4b) for the research fellow; mean 
differences were 74.6 µm (IQR 58.5) and 55.2 µm (IQR 
54.8), respectively.
Fig. 2  Exclusion of the patients (a), followed by the exclusion of the measurement locations (b)
Table 1  Patient demographics
IQR interquartile range, CI confidence interval
For N = 57
Age, mean in years (IQR) 64 (15.0)
BMI, mean in kg/m2(IQR) 29.2 (7.4)
Females [n (%)] 14 (24.6)
Prague length (cm)
 Circumferential, mean (95% CI) 2.7 (1.8-3.7)
 Maximum, mean (95% CI) 4.4 (3.4–5.4)
Histopathologic diagnosis
 NDBE [n (%)] 6 (10.5)
 IND [n (%)] 5 (8.8)
 LGD [n (%)] 28 (49.1)
 HGD [n (%)] 14 (24.6)
 EAC [n (%)] 4 (7)
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Interobserver Agreement
In order to validate these measurements, we compared the 
measurements of the research fellow with the measure-
ments of the VLE expert for both the original images and 
the contrast-enhanced images. The consistency of the meas-
urements between the research fellow and the VLE expert 
was “very good” for the contrast-enhanced images with 
an intra-class coefficient of 0.880 (95% CI 0.867–0.891; 
Table 4, Fig. 4c). The intra-class correlation coefficient of 
the measurements made from the original images was signif-
icantly lower (0.778; 95% CI 0.754–0.799 Table 4, Fig. 4d). 
The percentage of individual measurements that differed less 
than 142 µm (2 × SD of intra-observer mean difference of 
Fig. 3  Mean BET (µm) per 
patient ± 2 times the standard 
deviation
Table 2  Relationship between Barrett’s epithelial thickness and gen-
der, age, BMI, Prague length, and histopathologic diagnosis
SEM standard error of the mean, BMI body mass index
Based on patients 
mean thickness
Based on individual 
measurements
Correlation 
coefficient 
(r)
P value Correlation 
coefficient 
(r)
P value
Age (years) 0.163 0.225 0.030 0.243
BMI (kg/m2) − 0.49 0.718 − 0.073 0.005
Prague length (cm)
 Prague C 0.202 0.131 0.062 0.018
 Prague M 0.070 0.603 0.016 0.529
Histopathologic 
diagnosis
− 0.142 0.000 − 0.042 0.034
Table 3  Intra-observer 
variability in the contrast-
enhanced images between T1 
and T2
IQR interquartile range, CI confidence interval, T1 timepoint first measurements, T2 timepoint second 
measurements
VLE expert Research fellow
Mean BET (IQR)
 T1 436.2 (200.6) 395.6 (175.6)
 T2 448.6 (183.9) 398.5 (178.9)
Mean difference BET (µm) between T1 and T2 (IQR) 74.6 (58.5) 55.2 (51.8)
Percentage of measurements with an intra-observer differ-
ence < 142 microns
87.4% 89.7%
Time difference between T1 and T2 (months) 10 3
Intra-class coefficient (95% CI†) 0.818 (0.798–0.836) 0.890 (0.878–0.900)
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Fig. 4  Scatterplot displaying. (a) The intra-observer variability of the 
VLE expert between T1 and T2 for the contrast-enhanced images; 
(b) the intra-observer variability of the research fellow between T1 
and T2 for the contrast-enhanced images; (c) the interobserver vari-
ability between the VLE expert (T1) and the research fellow (T1) for 
the contrast-enhanced images; (d) the interobserver between the VLE 
expert and the research fellow for the “original” images
Table 4  Interobserver variability in the original images and the contrast-enhanced images
IQR interquartile range, CI confidence interval
Original images (T1) Contrast-enhanced images (T1) P value
Mean BET (IQR)
 VLE expert 485.3 (225.7) 436.2 (200.6) –
 Research fellow 398.5 (178.9) 395.6 (175.6)
Mean difference BET (µm) between two raters (IQR) 113.8 (108.8) 76.0 (75.2) < 0.001
Percentage of measurements with an interobserver differ-
ence < 142 μm
74.1% 86.6% < 0.001
Intra-class coefficient (95% CI) 0.778 (0.754–0.799) 0.880 (0.867–0.891) P < 0.05
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the research fellow) in the contrast-enhanced and original 
images was 74.1% and 86.6%, respectively.
Discussion
In this paper, we report the use of a surface flattening and 
contrast enhancement algorithm for simplified and reliable 
BET measurements. Interobserver agreement using the 
contrast-enhanced images was significantly higher than for 
non-contrast-enhanced images, demonstrating the capabil-
ity of this algorithm to clarify BE epithelial boundaries in 
VLE images. A wide range of BET was identified between 
patients, which is a potential explanation of the variable 
response to RFA.
Ganz et al. [2] were the first to ablate esophageal epithe-
lium and found a uniform ablation depth in animal and post 
esophagectomy specimens. When applied to human stud-
ies and subsequent standard clinical care, there were little 
empirical data about how to optimize RFA dosing to ensure 
sufficient depth of ablation while minimizing the chance of 
overtreatment and stricture formation. The optimal RFA 
dosage is still unclear [4].
Until recently, no available imaging technology had been 
capable of reliable BET measurement for the guidance of 
RFA treatment. Confocal laser endomicroscopy (CLE), 
endoscopic ultrasound (EUS), and VLE are three com-
monly used esophageal imaging technologies. CLE can pro-
vide real-time, transverse or en-face, microscopic imaging, 
showing cellular and subcellular details. CLE can detect BE 
neoplasia with a sensitivity and specificity of 90.4% (95% CI 
71.9–97.2) and 92.7% (95% CI 87–96), respectively, which 
are superior to those of conventional endoscopy [10, 11]. 
However, since CLE is a transverse imaging modality, it is 
incapable of measuring mucosal thickness and therefore not 
suitable for BET assessment.
EUS is a cross-sectional imaging modality that can 
image at depths of up to 5–6 cm, yet has limited resolution 
(100 µm). Srivastava et al. [12] and Gill et al. [13] used 
EUS to measure wall thickness as a proxy to BET. In both 
studies, thickness was defined as the distance from the bal-
loon–mucosa interface to the outermost hyperechoic line, 
histologically equal to the adventitia, and found a signifi-
cantly greater esophageal wall thickness with columnar lined 
tissue. Because of its relatively low resolution, EUS cannot 
diagnose BE or precisely identify the epithelial boundaries. 
EUS is therefore not likely suitable for BET measurement 
[13].
VLE is an imaging technique that can detect BE dysplasia 
with a sensitivity, specificity, and accuracy of 86%, 88%, and 
87%, respectively, using the VLE-DA algorithm [14]. Tsai 
et al. [15] assessed mucosal thickness in thirty-three patients 
with the first-generation OCT device (lateral resolution 
15 µm, axial resolution 5 µm, imaging depth of 1–2 mm) 
by measuring the vertical distance between the epithelial 
surface and the deepest edge of the lamina propria/muscu-
laris mucosa layer at the location with the best balloon–sur-
face contact. They found that a Barrett’s mucosal thickness 
of > 333 µm could predict the presence of BE at 6–8 weeks 
follow-up with an accuracy of 87.9% [15]. Despite the small 
sample size and their addition of the lamina propria and 
muscularis mucosa to the measurements, these findings sup-
port the hypothesis that BET is a factor that governs RFA 
response and confirms the need of further research that cor-
relates epithelial thickness to RFA treatment response.
Given the large amount of image data produced by the 
second-generation OCT VLE technology, to implement epi-
thelial thickness measurements into clinical practice, quick 
(i.e., < 30 s) real-time image analysis by a computer-aided 
system would be helpful. Swager et al. [16] and Sommen 
et al. [17] already showed superiority of a computer-aided 
system for the recognition of BE neoplasia and early cancer, 
if compared to expert opinion. This previously developed 
computer-aided system could be combined with a com-
bined lamina propria recognition, contrast enhancement, 
and attenuation compensation algorithm for real-time BET 
measurements.
A potential limitation of our paper is that there is no 
direct corresponding histopathology gold standard available 
for the comparison of our measurements. As a result, we 
cannot assess the accuracy of our BET measurement algo-
rithm. Other groups, however, have precisely correlated the 
VLE imaging landmarks used in this study with the same 
histological/anatomical landmarks (e.g., muscularis mucosa, 
lamina propria) [17]. A strength of our study was the high 
degree of intra- and interobserver reproducibility of our 
technique which suggests that these measurements will be 
consistent across studies and observers.
Interestingly, thickness appeared to vary along the Bar-
rett’s segment of each patient (Fig. 3). In our opinion, this 
suggests that treatment may need to be personalized to each 
patient and even each segment. Once the system has been 
optimized, it could be integrated into the delivery catheter 
to give precisely the right dose of ablation according to loca-
tion to achieve optimal ablation depth, increased treatment 
response, and reduced stricture formation.
The inclusion of the patients and the different cross sec-
tions were random. However, the exclusion of the measure-
ment locations was done during the measurements, which 
could lead to a measurement-location selection bias. It is 
likely that this is not significant, as we implemented well-
defined criteria for exclusion (no BE tissue, surface find-
ing algorithm failed), and therefore, our exclusion metrics 
were likely reproducible and unbiased. Another limitation of 
our method is that it was manual and time consuming. The 
mean number of measurements per patient was 26 (95% CI 
1586 Digestive Diseases and Sciences (2019) 64:1579–1587
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21–31). Automation of the measurement of mean thickness 
per patient would be more precise and rapid and such meth-
ods are being developed. BET was significantly correlated 
with BMI, Prague C length, and dysplasia grade. However, 
the limited clinical value of low correlation coefficients has 
to be taken into account.
In conclusion, we have developed an algorithm to dis-
tinguish different BE mucosal layers and measure BET. 
We showed natural variation in mean thickness between 
patients and improved interobserver consistency by per-
forming measurements in attenuation-compensated, con-
trast-enhanced VLE images. Further research is needed to 
correlate epithelial thickness with treatment response and to 
automate BET measurements for real-time assessment and 
implementation into clinical practice.
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